Replies to post #141875 on Biotech Values

[DewDiligence]

VRTX/JAK class—[Biotech Jim]: initially starting with non-selective agents and then getting more selective…

[kamehameha]: that's why the JAK3 inhibitor VX-509 is a good bet!

It’s premature to say this, IMO. JAK3 specificity could turn out to be why VX-509 is a bad bat relative to the other JAK inhibitors in development.